- Home
- GOSS
GOSS
Gossamer Bio Inc.
as 05-20-2024 2:34pm EST
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
| Founded: | 2015 | Country: | United States |
| Employees: | 135 | City: | SAN DIEGO |
| Market Cap: | 157.0M | IPO Year: | 2019 |
| Target Price: | $8.60 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $1.88 | Next Earning Date: | 05-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Gossamer Bio Inc. (GOSS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Christian Waage | GOSS | EVP, Tech Ops and Admin | Mar 27 '24 | Sell | $1.16 | 6,430 | $7,429.87 | 585,934 | SEC Form 4 |
| Giraudo Bryan | GOSS | COO/CFO | Mar 27 '24 | Sell | $1.16 | 6,430 | $7,430.51 | 92,737 | SEC Form 4 |
| Hasnain Faheem | GOSS | President & CEO | Mar 27 '24 | Sell | $1.16 | 23,172 | $26,772.93 | 120,293 | SEC Form 4 |
| Peterson Caryn | GOSS | EVP, Regulatory Affairs | Mar 18 '24 | Sell | $1.33 | 4,018 | $5,342.73 | 49,833 | SEC Form 4 |
Latest Gossamer Bio Inc. News
GOSS Breaking Stock News: Dive into GOSS Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Business Wire
10 days ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Associated Press Finance
13 days ago
Gossamer Bio: Q1 Earnings Snapshot
Business Wire
13 days ago
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Pharmaceutical Technology
13 days ago
Gossamer Bio and Chiesi partner for pulmonary hypertension treatment
Pharmaceutical Technology
13 days ago
Gossamer Bio and Chiesi link for pulmonary hypertension treatment
Benzinga
14 days ago
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Reuters
14 days ago